Humana Inc. (NYSE:HUM) Stock Holdings Trimmed by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Humana Inc. (NYSE:HUM) by 38.5% during the first quarter, Holdings Channel.com reports. The firm owned 2,399,204 shares of the insurance provider’s stock after selling 1,498,902 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Humana were worth $831,853,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of HUM. Barlow Wealth Partners Inc. acquired a new position in Humana during the 4th quarter valued at about $1,977,000. Auxano Advisors LLC acquired a new position in shares of Humana during the 4th quarter valued at $540,000. Intech Investment Management LLC raised its stake in shares of Humana by 46.2% in the 4th quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after buying an additional 13,356 shares in the last quarter. AdvisorShares Investments LLC acquired a new stake in shares of Humana in the fourth quarter valued at $421,000. Finally, Sei Investments Co. boosted its stake in Humana by 0.4% during the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after buying an additional 264 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HUM. Piper Sandler initiated coverage on shares of Humana in a report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target for the company. Wells Fargo & Company cut their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Oppenheimer reduced their target price on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Barclays dropped their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Finally, TD Cowen raised their price objective on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $402.60.

Humana Stock Performance

Shares of HUM stock traded up $6.23 during trading hours on Friday, reaching $392.63. 1,003,973 shares of the company’s stock were exchanged, compared to its average volume of 1,301,923. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $47.31 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.27 and a beta of 0.51. The business has a fifty day moving average price of $365.66 and a 200-day moving average price of $347.02.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the company earned $9.38 EPS. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. Analysts predict that Humana Inc. will post 16.27 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.